NUEVOS MODELOS NANOTECNOLÓGICOS EN EL DISEÑO DE PIEL ARTIFICIAL CON NANOPARTÍCULAS PARA EL RECUBRIMIENTO DE PRÓTESIS DE MANO Y PIERNA EN DISCAPACITADOS

El artículo trata sobre la investigación y el desarrollo de una nueva metodología el desarrollo de modelos nanotecnológicos de acuerdo a una metodología de diseño, implementación de recubrimientos y mantenimiento, para la captura, transformación, almacenamiento y extracción de datos, de la piel artificial con nanopartículas para el recubrimiento de prótesis; equipándolo con un sistema de adquisición de datos que tome las señales de su par biológico y luego sean replicadas en la prótesis usando técnicas de inteligencia artificial

Synthesis, leishmanicidal, trypanocidal and cytotoxic activities of quinoline-chalcone and quinoline-chromone hybrids

We report herein the synthesis and biological activities (cytotoxicity, leishmanicidal and trypanocidal) of six quinoline-chalcone and five quinoline-chromone hybrids. The synthesized compounds were evaluated against amastigotes forms of Leishmania (V) panamensis, which is the most prevalent Leishmania species in Colombia and Trypanosoma cruzi, which is the major pathogenic species to humans. Cytotoxicity was evaluated against human U-937 macrophages. Compounds 8–12, 20, 23 and 24 showed activity against Leishmania (V) panamensis, while compounds 9, 10, 12, 20 and 23 had activity against Trypanosoma cruzi with EC50 values lower than 18 mg mL−1. 20 was the most active compound for both Leishmania (V) panamensis and Trypanosoma cruzi with EC50 of 6.11 ± 0.26 μg mL−1 (16.91 μM) and 4.09 ± 0.24 (11.32 μM), respectively. All hybrids compounds showed better activity than the anti-leishmanial drug meglumine antimoniate. Compounds 20 and 23 showed higher activity than benznidazole, the current anti-trypanosomal drug. Although these compounds showed toxicity for mammalian U-937 cells,they still have the potential to be considered as candidates to antileishmanial or trypanocydal drug development

Treatment with sotrovimab for SARS-CoV-2 infection in a cohort of high-risk kidney transplant recipients.

Sotrovimab is a neutralizing monoclonal antibody (mAb) that seems to remain active against recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. The evidence on its use in kidney transplant (KT) recipients, however, is limited. We performed a multicenter, retrospective cohort study of 82 KT patients with SARS-CoV-2 infection {coronavirus disease 2019 [COVID-19]} treated with sotrovimab. Median age was 63 years. Diabetes was present in 43.9% of patients, and obesity in 32.9% of patients; 48.8% of patients had an estimated glomerular filtration rate under 30 mL/minute/1.73 m2. Additional anti-COVID-19 therapies were administered to 56 patients, especially intravenous steroids (65.9%). Sotrovimab was administered early ( Sotrovimab had an excellent safety profile, even in high-comorbidity patients and advanced chronic kidney disease stages. Earlier administration could prevent progression to severe disease, while clinical outcomes were poor in patients treated later. Larger controlled studies enrolling KT recipients are warranted to elucidate the true efficacy of monoclonal antibody therapies

Smart Technologies. SmartTech-IC 2021: Proceedings of the Second International Conference on Smart Technologies, Systems and Applications

This book contains a group of selected papers, which were presented at the Second International Conference on Smart Technologies, Systems and Applications (SmartTech-IC 2021) held on December 1-3, 2021 in Quito, Ecuador. The SmartTech-IC conference aims to attract researchers, scientists and technologists from some of the top companies, universities, research groups, and government agencies from Latin America and around of the world to communicate their research results, inventions and innovative applications in the area of smart science and the most recent smart technological trends. The second edition of SmartTech-IC conference was organized by the Universidad Politécnica Salesiana (Campus Giron), a private institution of higher education with social purposes, nonprofit and co-financed from the Ecuadorian State. The SmartTech-IC conference has been conceived as an academic platform to promote the creation of technical and scientific collaboration networks. The goal of the conference was addressed some relevant topics related to smart technologies, smart systems, smart trends and applications in different domains in the field of computer science and information systems that represent innovation in current society